Thoughts On Celgene Rising Despite Negative News Today

9/8/17

Introduction - Celgene not as strong as Hurricane Irma, but pretty strong nonetheless

The biotech I have championed most strongly for the past 11 months, Celgene (NASDAQ:CELG), had a positive technical turnaround Thursday after trading down 2% on adverse news relating to a major clinical trial program. This article explores the bad news and provides some thoughts on why traders may have bought this dip so aggressively.

Just last week, I wrote an article focused heavily on the valuation of CELG. This article focuses mostly on fundamentals that underpin the valuation, with some additional comments on the updated technicals. So in a sense, this article serves as a Part 2 of a two-part series.

First up, the negative news that the market has shrugged off for now.

READ FULL ARTICLE HERE

It's on us. Share your news here.

Submit your stories and articles to citybizlist today.